期刊文献+

JAB1在胃癌组织中的表达及临床意义 被引量:1

Expression of JAB1 and its clinical significance in gastric carcinom
下载PDF
导出
摘要 目的通过检测胃癌组织及相应癌旁组织中的C-JUN激活域结合蛋白(C-JUN activation domain binding protein,JAB1)的表达,探讨JAB1在胃癌的表达与临床病理参数及预后的关系。方法应用免疫组织化学方法(SP法)检测60例胃癌及相应癌旁组织中JAB1的表达情况,并分析其表达与胃癌分化程度、临床分期、淋巴结转移等临床病理参数及预后的关系。结果 JAB1在胃癌组织的阳性表达率为71.7%(43/60),癌旁组织的阳性表达率为23.3%(14/60),两者比较差异有统计学意义(χ2=28.104,P<0.001)。JAB1蛋白在胃癌组织的表达与组织分化程度、浸润深度和淋巴转移显著有关(P<0.05),与患者性别、年龄、肿瘤大小、大体分型、远处转移无关(P>0.05)。癌组织JAB1阳性表达患者5年生存率为43.4%,显著低于阴性患者的64.7%(P<0.05)。结论 JAB1在胃癌组织中高表达,其表达与胃癌分化程度、浸润及淋巴转移及预后相关,参与胃癌的发生、发展,有望成为胃癌诊治的新靶点。 Objective To investigate JAB1expression and its clinical role in gastric cancer.Methods The expression of C-JUN activation domain bingding protein1(JAB1) was examined in tumor tissues and paratumor tissues from 60 gastric cancer patients by immunohistochemical SP technique. The relationships between JAB1 expression and clinocopathological features and survival were analyzed. Results The positive expression rate of JAB1 in gastric cancer was 71.7%(43 / 60), significantly higher than 23.3%in the paratumor tissues(χ2=28.104,P <0.001). The expression of JAB1 protein was correlated with differentiation degree, infiltrative depth and lymphatic metastasis(P<0.05), but not with sex, age, tumor size, gross classifications and distant metastasis(P>0.05). The 5-year survival rate of the patients with positive JAB1 expression was 43.4%, significantly lower than 64.7% of those with negative JAB1 expression(P <0.05). Conclusions JAB1 is highly expressed in gastric cancer, and correlated with tumor differentiation, infiltration, lymph metastasis and prognosis.It is expected that JAB1 may be a new target for diagnosis and treatment of gastric cancer.
出处 《消化肿瘤杂志(电子版)》 2013年第2期88-91,共4页 Journal of Digestive Oncology(Electronic Version)
关键词 JAB1 胃癌 预后 JAB1 Gastric cancer Clinicopathology
  • 相关文献

参考文献4

二级参考文献28

  • 1Kouvaraki MA, Korapati AL, Rassidakis GZ, et al. Potential role of Jun activation domain-binding protein 1 as a negative regulator of P27^kip1 in pancreatic adenocarcinoma [ J ]. Cancer Res, 2006, 66:8581 -8589.
  • 2Osoegawa A, Yoshino I, Kometani T, et al. Overexpression of Jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features [ J ]. Cancer, 2006, 107 : 154 - 161.
  • 3Wang Yuchan, Fei Min, Cheng Chun, et al. Jun Activation Domain-Binding Protein 1 negatively regulate p27 ( kipl ) in Non-Hodgkin's Lymphomas. [ J ]. Cancer Biol Ther, 2007, 7(3) : 460 -467.
  • 4Patil MA, Gutgemann I, Zhang J, et al. Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jabl as a potential target for 8q gain in hepatocellular carcinoma [ J ]. Carcinogenesis, 2005,26 : 2050 - 2057.
  • 5Marrero JA, Fontana R J, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort[ J]. Hepatology, 2005, 41 : 707 - 716.
  • 6Parcellier A, Brunet M, Schmitt E, et al. HSP27 favors ubiquitination and proteasomal degradation of P27^kip1 and helps S-phase re-entry in stressed cells [ J]. FASEB J, 2006, 20:1179 - 1181.
  • 7Claret FX,Hibi M,Dhut S,et al.A new group of conserved coactivators that increase the specificity of AP-1 transcription factors[J].Nature,1996,383(6599):453-457.
  • 8Kwok SF,Solano R,Tsuge T,et al.Arabidopsis homologs of a c-Jun coactivator are present both in monomeric form and in the COP9 complex,and their abundance is differentially affected by the pleiotropic cop/det/fus mutations[J].Plant Cell,1998,10(11):1779-1790.
  • 9Deng XW,Dubiel W,Wei N,et al.Unified nomenclature for the COP9 signalosome and its subunits; an essential regulator of development[J].Trends Genet,2000,16(7):289.
  • 10Pagano M,Tam SW,Theodoras AM,et al.Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27[J].Science,1995,269(5224):682-685.

共引文献3

同被引文献5

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部